SCHEMBL6041420

SCHEMBL6041420

O=C(O)N1CCC(c2ccc(OCc3nnc(-c4ccccc4)o3)cc2)C(O)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 5/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MAPT P10636 3/20 0.50
TP53 P04637 2/20 0.47
HPGD P15428 3/20 0.46
GAA P10253 2/20 0.44
TSHR P16473 2/20 0.44
KDM4E B2RXH2 4/20 0.44
LMNA P02545 1/20 0.44
KCNH2 Q12809 2/20 0.43
MCHR1 Q99705 2/20 0.43
PKM P14618 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6042651 0.82 REN (0.50) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL6956029 0.82 MEN1 (0.51) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL3069231 0.81 NPC1 (0.52) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL6042557 0.79 RAB9A (0.53) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL6043844 0.78 MEN1 (0.45) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL3193386 0.77 RAB9A (0.45) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6041843 0.77 RAB9A (0.45) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6041847 0.76 REN (0.44) NPC1RAB9ASMN1; SMN2TP53
SCHEMBL6042191 0.75 KMT2A (0.42) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL6041582 0.75 MEN1 (0.42) MEN1KMT2ANPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 MEN1 2561/4885KMT2A 2702/4885POLB 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.